Savara Inc Dossier - Source-backed chat

Savara Inc

SVRANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.04Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1B

Enterprise Value $1B

Shares Outstanding 205.5M diluted

Next Earnings Date22 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Savara Inc. represents a high-conviction, late-stage biopharmaceutical opportunity centered on its lead asset, MOLBREEVI (molgramostim inhalation solution), for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). With positive Phase 3 IMPALA-2 data demonstrating statistically significant improvements in pulmonary gas transfer (DLco%) and quality of life, MOLBREEVI is positioned to become the first and only approved pharmacological therapy for this rare, debilitating lung disease. Although the FDA extended the PDUFA target action date to November 22, 2026, to review additional information, the agency cited no concerns regarding safety, efficacy, or manufacturing. Backed by a robust cash position of approximately $202.8 million as of Q1 2026 and access to up to $150 million in non-dilutive capital upon approval, Savara is well-capitalized to execute its global commercial launch.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$10.94

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0015%

The FDA issues a Complete Response Letter (CRL) or demands additional clinical trials due to CMC or device-related issues with the eFlow Nebulizer System, pushing approval timelines past 2027. The delay severely depletes Savara's cash runway, forcing highly dilutive equity financing. European and UK regulatory reviews are similarly delayed, and the $150 million in non-dilutive capital remains inaccessible, significantly damaging the company's valuation.

Base CaseCentral scenario

$10.9460%

Matches the consensus mean

MOLBREEVI is approved by the FDA by the extended PDUFA date of November 22, 2026. The company initiates a structured U.S. commercial launch in late 2026/early 2027, targeting specialized pulmonologists. European and UK regulatory reviews progress standardly with approvals in mid-2027. Savara utilizes its existing cash reserves and draws down a portion of its non-dilutive capital to fund launch preparations, achieving breakeven and profitability by 2028 in line with consensus expectations.

Bull CaseUpside scenario

$16.0025%

MOLBREEVI receives rapid FDA approval on or before the November 22, 2026 PDUFA date with a clean label and no restrictive REMS. Commercial uptake is accelerated by high unmet medical need among the estimated 5,500 diagnosed aPAP patients in key markets. European (EMA) and UK (MHRA) approvals follow shortly in early 2027, triggering the full $150 million in non-dilutive debt and royalty funding. Peak global sales exceed the consensus estimate of $500 million, driving the company to profitability ahead of the 2028 target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class asset (MOLBREEVI) targeting a rare disease (aPAP) with no currently approved pharmacological treatments, offering a strong first-mover advantage.
Robust clinical evidence from the global Phase 3 IMPALA-2 trial showing statistically significant improvements in primary and secondary endpoints (DLco%, SGRQ, and exercise capacity).
Strong financial position with $202.8 million in cash and short-term investments as of March 31, 2026, plus access to $150 million in non-dilutive capital upon FDA approval.
Orphan Drug, Breakthrough Therapy, and Fast Track designations in the U.S., alongside Promising Innovative Medicine and Innovation Passport designations in the UK, providing regulatory exclusivity and support.

Key Investment Risks

Extreme single-asset risk, as Savara's valuation is almost entirely dependent on the regulatory and commercial success of MOLBREEVI.
Regulatory delay risk, as evidenced by the three-month PDUFA date extension to November 22, 2026, following the FDA's classification of information responses as a major amendment.
Commercial execution risk in a highly specialized, niche orphan drug market with a small, concentrated patient population.
Upcoming leadership transition risk as Robert Lutz prepares to assume the combined CFO/COO role on July 15, 2026, amid critical launch preparations.

Thesis Invalidation Triggers

A Complete Response Letter (CRL) or regulatory rejection of the MOLBREEVI BLA by the FDA on or before November 22, 2026.
Safety signals or serious adverse events emerging from the ongoing open-label extension period of the IMPALA-2 trial.
Failure to secure regulatory approvals or experiencing severe delays with the EMA or MHRA applications.
Significant cash burn acceleration that exhausts the cash runway prior to commercial commercialization and non-dilutive capital access.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.